首页> 美国卫生研究院文献>British Journal of Cancer >Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer
【2h】

Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer

机译:头颈部鳞状细胞癌中的共同靶向EGFR和IKKβ/NF-κB信号通路:头颈部鳞状细胞癌的潜在新疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inhibition of cell proliferation by co-targeting EGFR and IKK in HNSCC cells. – Gefitinib and IKKβ inhibitor CmpdA synergistically inhibit cell proliferation. Cal27 ( ), FaDu, ( ) and SCC25 ( ) cells were treated with DMSO, Gefitinib, CmpdA or a combination for 72 h and cell proliferation was determined by the MTS assay. The experiments were performed in triplicate, and the results are representative of three independent experiments. The combination index values (CI values) were determined using the CalcuSyn software. – Synergistic inhibition of colony formation by Gefitinib and CmpdA combination. Cal27 ( ), FaDu, ( ) and SCC25 ( ) cells were treated with DMSO, Gefitinib, CmpdA or a combination for 24 h and colony formation was observed 10 days after treatment. Each experiment was repeated three times
机译:通过共同靶向HNSCC细胞中的EGFR和IKK抑制细胞增殖。 –吉非替尼和IKKβ抑制剂CmpdA协同抑制细胞增殖。用DMSO,吉非替尼,CmpdA或组合将Cal27(),FaDu()和SCC25()细胞处理72 h,并通过MTS分析确定细胞增殖。实验一式三份进行,结果代表了三个独立的实验。使用CalcuSyn软件确定组合指数值(CI值)。 –吉非替尼和CmpdA组合协同抑制菌落形成。用DMSO,吉非替尼,CmpdA或组合将Cal27(),FaDu,()和SCC25()细胞处理24小时,并在处理后10天观察到菌落形成。每个实验重复三遍

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号